Join
Live feed
·
PRReleasevia Quantisnow
Mesoblast Limited logo

Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

ByQuantisnow·Wall Street's wire, on your screen.
MESO· Mesoblast Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MESO (Mesoblast Limited) and more on Quantisnow.